FDA Grants Fast Track to CytomX’s Varseta-M in Relapsed Metastatic Colorectal Cancer
FDA grants Fast Track to CytomX’s Varseta-M for relapsed metastatic colorectal cancer as a 2027 pivotal trial and new combinations approach.
Already have an account? Sign in.